HomeCompareEKTAY vs SCHD

EKTAY vs SCHD: Dividend Comparison 2026

EKTAY yields 2.25% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EKTAY wins by $17.5K in total portfolio value· pulled ahead in Year 5
10 years
EKTAY
EKTAY
● Live price
2.25%
Share price
$5.74
Annual div
$0.13
5Y div CAGR
33.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.6K
Annual income
$7,846.63
Full EKTAY calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — EKTAY vs SCHD

📍 EKTAY pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKTAYSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKTAY + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKTAY pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKTAY
Annual income on $10K today (after 15% tax)
$191.36/yr
After 10yr DRIP, annual income (after tax)
$6,669.64/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, EKTAY beats the other by $6,307.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKTAY + SCHD for your $10,000?

EKTAY: 50%SCHD: 50%
100% SCHD50/50100% EKTAY
Portfolio after 10yr
$37.8K
Annual income
$4,136.28/yr
Blended yield
10.95%
📊

Analyst Conviction Gap

Where Wall Street is split right now

EKTAY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.3
Piotroski
4/9
SCHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKTAY buys
0
SCHD buys
0
No recent congressional trades found for EKTAY or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKTAYSCHD
Forward yield2.25%3.46%
Annual dividend / share$0.13$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.3%0%
Portfolio after 10y$46.6K$29.0K
Annual income after 10y$7,846.63$425.95
Total dividends collected$23.3K$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EKTAY vs SCHD ($10,000, DRIP)

YearEKTAY PortfolioEKTAY Income/yrSCHD PortfolioSCHD Income/yrGap
1$11,000$300.10$11,226$346.36$226.00SCHD
2$12,181$411.25$12,572$357.38$391.00SCHD
3$13,601$567.35$14,046$367.84$445.00SCHD
4$15,343$789.20$15,660$377.73$317.00SCHD
5← crossover$17,526$1,109.05$17,425$387.07+$101.00EKTAY
6$20,331$1,578.24$19,354$395.86+$977.00EKTAY
7$24,035$2,280.85$21,461$404.13+$2.6KEKTAY
8$29,076$3,359.15$23,762$411.89+$5.3KEKTAY
9$36,174$5,062.63$26,272$419.15+$9.9KEKTAY
10$46,553$7,846.63$29,010$425.95+$17.5KEKTAY

EKTAY vs SCHD: Complete Analysis 2026

EKTAYStock

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Full EKTAY Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this EKTAY vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKTAY vs JEPIEKTAY vs OEKTAY vs KOEKTAY vs MAINEKTAY vs VYMEKTAY vs DGROEKTAY vs VIGEKTAY vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.